Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pescara – page 2

64 clinical trials in Pescara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pescara at a glance
64
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

64 trials in Pescara

Open in trial search

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Myelodysplastic syndrome

Recruiting

Study on Luspatercept for Treating Anemia in Patients with Myelodysplastic Syndromes (MDS) with del5q, Resistant to Prior Treatments and Needing Blood Transfusions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Associazione Qol-One

Acute myeloid leukaemia

Recruiting

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Diffuse large B-cell lymphoma

Recruiting

Study of Rituximab and Golcadomide for Older Frail Patients with Diffuse Large B-cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Golcadomide
  • Sponsor:Fondazione Italiana Linfomi Ets

Hairy cell leukaemia

Recruiting

Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Universita Degli Studi Di Perugia

Acute myeloid leukaemia

Recruiting

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amsacrine
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Myelodysplastic syndrome

Recruiting

Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Follicular lymphoma

Recruiting

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Non-Hodgkin's lymphoma

Recruiting

Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cyclophosphamide
  • Sponsor:Universitaetsklinikum Muenster AöR

Colorectal cancer metastatic

Recruiting

Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Pescara

What the registry says about research in the country

01 Hematologic Malignancies

Clinical trials focusing on acute myeloid leukemia (AML) and multiple myeloma, evaluating novel therapeutic approaches including chemotherapy-free alternatives and targeted treatments.

  • Leukemia therapies
  • Novel drug combinations
  • Targeted treatments

Studies explore innovative treatment strategies, including venetoclax combinations and immunotherapy approaches.

02 Lymphoma Research

Investigations into follicular lymphoma and diffuse large B-cell lymphoma, testing shortened chemotherapy protocols combined with immunotherapy treatments.

  • Immunotherapy protocols
  • Treatment optimization
  • Response assessment

Research aims to improve treatment outcomes while reducing therapy duration and side effects.

03 Pediatric Oncology

Studies addressing acute lymphoblastic leukemia in children and adolescents, evaluating new treatment protocols and maintenance strategies.

  • Childhood leukemia
  • Lymphoblastic lymphoma
  • Treatment protocols

Focus on developing more effective and less toxic treatment approaches for young patients.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.